Presentation is loading. Please wait.

Presentation is loading. Please wait.

A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous.

Similar presentations


Presentation on theme: "A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous."— Presentation transcript:

1 A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization  Hosam El Sayed, MD, PhD, Richard Kerensky, MD, Michael Stecher, MD, Prasant Mohanty, MBBS, Mark Davies, MD, PhD  Journal of Vascular Surgery  Volume 63, Issue 1, Pages e1 (January 2016) DOI: /j.jvs Copyright © 2016 Society for Vascular Surgery Terms and Conditions

2 Fig 1 Patient flow diagram.
Journal of Vascular Surgery  , e1DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions

3 Fig 2 The Kaplan-Meier curve compares the cumulative freedom from restenosis at long-term follow-up. The trend in the treatment benefit observed at 4 months after the procedure (restenosis rates of 9% in the standard of care [SOC] group and 0% in the Xilonix group) diminished during the course of the study. At 12 months, the restenosis rates were not different between the Xilonix and SOC groups; 27% (6 of 22) Xilonix patients and 24% (5 of 21) SOC patients experienced target vessel restenosis (log-rank, P = .79). Journal of Vascular Surgery  , e1DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions


Download ppt "A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous."

Similar presentations


Ads by Google